APAC CIOOutlook

Advertise

with us

  • Technologies
      • Artificial Intelligence
      • Big Data
      • Blockchain
      • Cloud
      • Digital Transformation
      • Internet of Things
      • Low Code No Code
      • MarTech
      • Mobile Application
      • Security
      • Software Testing
      • Wireless
  • Industries
      • E-Commerce
      • Education
      • Logistics
      • Retail
      • Supply Chain
      • Travel and Hospitality
  • Platforms
      • Microsoft
      • Salesforce
      • SAP
  • Solutions
      • Business Intelligence
      • Cognitive
      • Contact Center
      • CRM
      • Cyber Security
      • Data Center
      • Gamification
      • Procurement
      • Smart City
      • Workflow
  • Home
  • CXO Insights
  • CIO Views
  • Vendors
  • News
  • Conferences
  • Whitepapers
  • Newsletter
  • Awards
Apac
  • Artificial Intelligence

    Big Data

    Blockchain

    Cloud

    Digital Transformation

    Internet of Things

    Low Code No Code

    MarTech

    Mobile Application

    Security

    Software Testing

    Wireless

  • E-Commerce

    Education

    Logistics

    Retail

    Supply Chain

    Travel and Hospitality

  • Microsoft

    Salesforce

    SAP

  • Business Intelligence

    Cognitive

    Contact Center

    CRM

    Cyber Security

    Data Center

    Gamification

    Procurement

    Smart City

    Workflow

Menu
    • Cloud
    • Cyber Security
    • Hotel Management
    • Workflow
    • E-Commerce
    • Business Intelligence
    • MORE
    #

    Apac CIOOutlook Weekly Brief

    ×

    Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Apac CIOOutlook

    Subscribe

    loading

    THANK YOU FOR SUBSCRIBING

    • Home
    • Cloud
    Editor's Pick (1 - 4 of 8)
    left
    Sustainable Future through Innovative Technology Solutions

    Faisal Parvez, Director, BT Business CIO

    Brokering the Cloud Services

    Eric Boyette, Secretary & State CIO, Information Technology

    Defining a Cloud Strategy: A Higher Education Paradigm

    Russell M. Kaurloto, VP and CIO, Clemson University

    Cloud or On-Premise? When Would The Question End?

    Kevin Soh, CIO and Director, e-Strategies, BH Global Corporation

    The Role of CIO in the Cloud-First World

    Yvonne Wassenaar, CIO, New Relic, Inc

    Epsilon Telecommunications: Bringing Agility in Business with Cloud

    CEO

    Prime Focus Technologies : Media ERP To Drive Creative Enablement And Realize New Monetization Oppor

    Founder and CEO, Prime Focus

    Lacima: Global Commodity Energy Portfolio Risk Analytics

    Co-founder, Lacima

    right

    How We're Leveraging New Technological Advancements By Building A Cell & Gene Therapy Business Unit Within An Established Pharmaceutical Company

    Marianthi Psacha, President, Head Europe, Middle East & Africa, Santen Pharmaceutical

    Tweet
    content-image

    Marianthi Psacha, President, Head Europe, Middle East & Africa, Santen Pharmaceutical

    In recent years, cell and gene therapies have been redefining the treatment paradigm in a number of disease areas. These therapies offer the potential to change the lives of patients suffering from previously incurable conditions. Santen being a company focused on ophthalmology, fully committed to reducing the loss of social and economic opportunities for people with eye conditions, it feels natural as well as necessary for us to expand into this promising field.

    For the past 130 years, Santen has been contributing to people’s eye health, expanding to cover over 60 countries and reaching the number 1 position in the Japanese and Chinese ophthalmic markets. As part of our new vision towards 2030, we are focusing on building our capabilities in order to leverage new technological advancements. We recently established a dedicated, global Cell & Gene Therapy business unit, committed to changing the lives of patients with inherited retinal diseases through transformative solutions.

    As we create a high-performing, sustainable and scalable platform for cell and gene therapies, we have aimed to maintain an intricate balance between leveraging the expertise and footprint we benefit from as an established, specialized pharmaceutical company, and developing new skills and capabilities to ensure we are able to tackle the unique challenges linked to this field.

    The cell and gene therapy field is evolving rapidly and represents higher risks compared to existing technologies. Developing such therapies therefore requires an agile, adaptable and risk-tolerant mindset. We have built an incredibly diverse team with deep expertise and experience across the ophthalmology, retina and rare disease fields. Team members already have experience dealing with the unique go to market approach required for cell and gene therapies, linked to, for example the small patient population associated with rare diseases.

    Additionally, in this rapidly changing field, functional boundaries tend to dissolve, requiring rapid input from all functions into key decisions. To ensure optimal cross-functionality, our platform builds on an integrated strategy of operations and commercialization.

    At the same time, we continue to leverage the existing expertise, market presence and relationships Santen has built over the years as a company with a deep heritage. Our team is guided by the overarching Santen vision of becoming a social innovator. Each and every team member strongly believes in the potential of cell and gene therapies to change the lives of patients living with inherited retinal dystrophies, a group of diseases for which there are currently very few approved treatments. With this in mind, we are fully committed to ensuring the success of current and future assets.

    Vision is essential to so many aspects of our daily lives- in addition to employment and education, it also plays a key role in our personal lives by allowing us to communicate with others

    Vision is essential to so many aspects of our daily lives- in addition to employment and education, it also plays a key role in our personal lives by allowing us to communicate with others. Without vision, we can’t carry out simple tasks we often take for granted, such as driving a car or changing a lightbulb. In new technological advancements, we see the potential to allow patients suffering from progressive sight loss, who currently do not have any treatment options available to them, an opportunity to participate in such activities. Through our expansion into cell and gene therapies, we see the potential to change lives.

    tag

    Pharmaceutical

    Weekly Brief

    loading
    Cloud Based Business Management Software of the Year - 2025
    ON THE DECK

    I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

    Read Also

    Loading...
    Copyright © 2025 APAC CIOOutlook. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Use and Privacy and Anti Spam Policy 

    Home |  CXO Insights |   Whitepapers |   Subscribe |   Conferences |   Sitemaps |   About us |   Advertise with us |   Editorial Policy |   Feedback Policy |  

    follow on linkedinfollow on twitter follow on rss
    This content is copyright protected

    However, if you would like to share the information in this article, you may use the link below:

    https://cloud.apacciooutlook.com/views/how-we-re-leveraging-new-technological-advancements-by-building-a-cell-gene-therapy-business-unit-within-an-established-pharmaceutical-company-nwid-9820.html